Promimic Past Earnings Performance
Past criteria checks 0/6
Promimic has been growing earnings at an average annual rate of 12.7%, while the Life Sciences industry saw earnings growing at 30.7% annually. Revenues have been growing at an average rate of 53.6% per year.
Key information
12.7%
Earnings growth rate
30.6%
EPS growth rate
| Life Sciences Industry Growth | 31.8% |
| Revenue growth rate | 53.6% |
| Return on equity | -12.0% |
| Net Margin | -23.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Promimic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 39 | -9 | 44 | 0 |
| 30 Sep 23 | 34 | -9 | 38 | 0 |
| 30 Jun 23 | 29 | -11 | 35 | 0 |
| 31 Mar 23 | 22 | -14 | 32 | 0 |
| 31 Dec 22 | 17 | -16 | 29 | 0 |
| 30 Sep 22 | 14 | -17 | 28 | 0 |
| 31 Dec 21 | 8 | -15 | 21 | 0 |
| 31 Dec 20 | 6 | -13 | 17 | 0 |
Quality Earnings: PRO is currently unprofitable.
Growing Profit Margin: PRO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PRO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (53.8%).
Return on Equity
High ROE: PRO has a negative Return on Equity (-12.02%), as it is currently unprofitable.